Is It Now Time To Buy Shire plc, Hold AstraZeneca plc & Sell Hikma Pharmaceuticals Plc?

Shire plc (LON:SHP) is better than AstraZeneca plc (LON:AZN), but Hikma Pharmaceuticals Plc (LON:HIK) is the best of all right now, argues this Fool.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shire (LSE: SHP) is bouncing back from its recent lows, but some risk still remains for its shareholders. The same holds true for AstraZeneca (LSE: AZN), yet I do not think that downside risk is any greater for Hikma (LSE: HIK) than for its two larger rivals.

Shire 

Its shares have traded in the 3,448p–5,870p range over the last twelve months, and currently change hands at around 4,800p . Shire’s performance since early August has been very poor but was not unexpected. As I argued last month, its stock was a straightforward investment until 4 August, but has since become a less obvious pick due to the ‘Shaxalta risk’ — the risk that Shire’s hostile approach for US biotech rival Baxalta will cost it north of $50 a share. 

There’s been talk that Baxalta may pursue acquisitions to prevent a takeover from Shire, so the biggest threat to value is that uncertainty may well persist into 2016, with Shire looking at similarly expensive targets if it fails to acquire Baxalta. Regardless of the outcome, Shire remains a strong long-term buy at this level based on fundamentals, trading multiples, geographical mix and several other factors — but if you are after short-term gains, it’s possible that your Christmas shopping may have to be financed by alternative sources!

Should you invest £1,000 in Lloyds Banking Group right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Lloyds Banking Group made the list?

See the 6 stocks

Hikma & Astra

Hikma’s strength has not surprised me at all over the last few weeks of trade. Indeed, its corporate strategy makes a lot of sense, while its capital allocation strategy — where it deploys cash, how much cash deployment costs to the firm, and what kind of capital is being deployed — is superb. Its equity value is up 25% this year spurred by deal-making, and its valuation has been resilient all the way through the summer. At 2,490p, its share price is only slightly lower than a 52-week high of 2,617p, but is much higher than a one-year low of 1,580p. 

Some pundits argue that Hikma is expensive based on its trading multiples, fundamentals and a few other elements, but I argue that you should gladly hold its stock as part of a diversified portfolio even if it were to trade north of 30x its forward earnings. Its balance sheet is sound, its core margins are rich and there’s plenty of growth kicking around — far from being a potential sell, this is a compelling buy in my view. End of story.

Over the last month, its performance on the stock exchange has been matched by that of Astra (+12%), but I’d not hold Astra stock instead. It’s priced at 30x forward earnings, which is a very high valuation for a defensive business that offers little growth and whose pipeline of drugs is not particularly attractive. 

I am bearish on Astra also because if I were to single out a truly appealing, mature pharmaceutical business whose stock trades at a significant discount to fair value right now, another obvious name would spring to mind.

But what does the head of The Motley Fool’s investing team think?

Should you invest £1,000 in Lloyds Banking Group right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Lloyds Banking Group made the list?

See the 6 stocks

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alessandro Pasetti has no position in any shares mentioned. The Motley Fool UK has recommended Hikma Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Content white businesswoman being congratulated by colleagues at her retirement party
Investing Articles

Age 60 and looking for income? 3 FTSE 100 shares yielding 6%+ to consider

Harvey Jones picks out three FTSE 100 shares that offer a juicy passive income stream. Older investors should consider them,…

Read more »

UK money in a Jar on a background
Investing Articles

One of Britain’s best dividend shares is soaring! Time to buy?

Our writer's been looking for shares to buy. One of the biggest UK dividend payers has caught his eye. Could…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing Articles

£100, £1,000, or £100,000? Here’s how much it takes to start investing in shares!

Does it take a large sum of money for someone to start investing in the stock market? Our writer doesn't…

Read more »

Close-up of a woman holding modern polymer ten, twenty and fifty pound notes.
Investing Articles

£20,000 in an ISA? Here’s how it could target £1,250 a month in passive income

A Stocks and Shares ISA can be a platform for someone with spare cash to set up a sizeable second…

Read more »

Close-up as a woman counts out modern British banknotes.
Investing Articles

3 UK shares I own for easy passive income

Christopher Ruane runs through a diverse trio of UK shares he currently owns, each of which generates passive income in…

Read more »

UK coloured flags waving above large crowd on a stadium sport match.
Investing Articles

Is the UK-US trade deal a brilliant buying opportunity for FTSE 100 shares?

A long-awaited trade deal has been struck between the UK and the US, but how much will FTSE 100 stocks…

Read more »

UK supporters with flag
Investing Articles

3 growth stocks up 27% in a month to consider buying now

Stock market volatility has been a brilliant opportunity to buy growth stocks, which are now rebounding at speed. Harvey Jones…

Read more »

Young happy white woman loading groceries into the back of her car
Investing Articles

This FTSE 250 stock has returned over 300% since 2020

After missing out on a 300% return from a FTSE 250 stock five years ago, Stephen Wright is ready for…

Read more »